Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CHRNA2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHRNA2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHRNA1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHRNA1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHMP7 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHMP7, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHMP5 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHMP5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
CTR20262400 Human Coagulation Factor IX (Yuanda Shuyang) Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into CTR20262400, evaluating Human Coagulation Factor IX (Yuanda Shuyang) in Hemorrhage: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
8 min read
CHMP4B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHMP4B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHMP2B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHMP2B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHMP2A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHMP2A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHKB Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHKB, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHKA Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHKA, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHIT1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHIT1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CHI3L2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CHI3L2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.